
    
      This was an open-label, randomized study to compare the following regimens with respect to
      toxicity and antitumor activity:

        -  the maximum tolerated dose (MTD) of ABI-007 300 mg/m^2 every 3 weeks;

        -  ABI-007 100 mg/m^2 administered weekly for 3 weeks with a 1 week rest;

        -  ABI-007 150 mg/m^2 administered weekly for 3 weeks with a 1 week rest;

        -  the standard dose and schedule of Taxotere (100 mg/m^2 every 3 weeks).
    
  